Tashkent, Uzbekistan (UzDaily.uz) — The Russian pharmaceutical company Geropharm has registered the drug Semavik in Uzbekistan. Containing the active ingredient semaglutide, the medication is intended for the treatment of type 2 diabetes and obesity.
Semavik is the first Russian equivalent of the Danish drug Ozempic and is already available to patients, the company’s press service reported.
According to the World Health Organization, nearly one in three residents of Uzbekistan — around 30% of the population — suffers from obesity. The International Diabetes Federation reports that in 2024, the prevalence of diabetes reached 1.5 million cases in the country.
Geropharm representatives emphasized that these figures highlight the growing burden of metabolic diseases on the healthcare system and confirm the need for effective and accessible therapeutic options.
Previously, Semavik was registered by the company in Azerbaijan, Kazakhstan, and Tajikistan.
